Clinical trials: sponsored by BeiGene
Healthy Volunteers
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
- Trial name
- NCT06906809
- Testing
- BGB-16673, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Participants, Healthy Subjects
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different…
- Conditions
- Healthy Participants, Healthy Subjects, Healthy Volunteers, Autoimmune Diseases
- Trial name
- NCT06342713
- Testing
- BGB-45035
- Where
- 13 sites in Australia, China and 1 more
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- BeiGene
Not Determined
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics of BGB-23339 and food effects in healthy participants
- Trial name
- NCT05093270
- Testing
- BGB-23339
- Where
- 3 sites in Australia, China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion…
- Trial name
- NCT06761898
- Testing
- BGB-43395
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
The purpose of this study is to determine the absorption, metabolism, and excretion of [14C]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male…
- Trial name
- NCT06776679
- Testing
- [14C]-BGB-16673
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of [14C]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma…
- Trial name
- NCT05844111
- Testing
- [14C]-BGB-11417
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects
Phase 1 study in healthy subjects to determine the effect of food on the pharmacokinetics of BGB-3111.
- Trial name
- NCT04163523
- Testing
- Zanubrutinib
- Where
- 5 sites in Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
Not Determined
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
This is a single-center, open-label, parallel group study designed to investigate the effect of CYP3A induction and inhibition following multiple doses of phenytoin (Part A) and itraconazole (Part B), respectively, on the…
- Trial name
- NCT06543043
- Testing
- Phenytoin, Itraconazole, sonrotoclax
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BeiGene
Tumor
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.
- Trial name
- NCT04472650
- Testing
- Sitravatinib
- Where
- Australia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants
- Trial name
- NCT04669262
- Testing
- BGB-DXP604, BGB-DXP593
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
Study to assess the relative bioavailability of zanubrutinib tablets compared to capsules and to evaluate the effects of food on the pharmacokinetics (PK) of the zanubrutinib tablet.
- Trial name
- NCT05547399
- Testing
- Zanubrutinib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
Study to determine the bioequivalence of a zanubrutinib tablet compared to capsules in healthy adult participants.
- Trial name
- NCT05767398
- Testing
- Zanubrutinib
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy, Male
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
- Trial name
- NCT04470908
- Testing
- Zanubrutinib, Rifabutin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- BeiGene
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.
- Trial name
- NCT05387668
- Testing
- BGB-23339
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
- Trial name
- NCT03432884
- Testing
- BGB-3111, Moxifloxacin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of [14C]-BGB-3111.
- Trial name
- NCT04163783
- Testing
- [14C]-BGB-3111, BGB-3111
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Subjects
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and…
- Trial name
- NCT03561298
- Testing
- BGB-3111 and Drug Cocktail
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteers: Asian, Non-Asian
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
Phase 1 study in healthy subjects to determine the effect of rifampin (Part A) or itraconazole (Part B) on the pharmacokinetics of BGB-3111
- Trial name
- NCT03301181
- Testing
- BGB-3111 (Arm A), Rifampin, BGB-3111 (Arm B)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BeiGene